J. Tirzepatide Continuation: 10 Week (up to 15mg/week)

 Requirement

All Weight Loss Kits include a telehealth consultation with our medical staff at no additional cost. Once approved, medications are ordered from the pharmacy and shipped out. If for any reason you are not approved, you will be refunded.

After purchase please fill out our new patient intake form: https://arfinnmed.com/intake/?pld=618

You may then schedule your TeleHealth Consultation:  https://agemanagementoptimalwellnesscenters.fullslate.com/

Approx. 20-30 lbs weight loss

Includes: Syringes, Alcohol Pads, TeleHealth Consultation

150 mg 

Important

Dosing must be followed exactly as prescribed. Use an injection on the same day each week.

Week 1 - 15 mg

Week 2 - 15 mg 

Week 3 - 15 mg 

Week 4 - 15 mg 

Week 5 - 15 mg 

Week 6  - 15 mg 

Week 7 - 15 mg 

Week 8 - 15 mg 

Week 9  - 15 mg 

Week 10 - 15 mg

Benefits

• Promotes major weight loss
• Lowers Blood Pressure
• Controls food cravings and reduces appetite
• Helps breakdown stored body fats
• Lowers BMI
• Helps reduce inflammation
• Improves gut health
• Lowers A1C
• Improves insulin resistance
• Plaque hemorrhage is reduced
• Lowers glucose levels
• Lowers cholesterol

How It Works

Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation.

Tirzepatide has been shown to decrease food intake and modulate fat utilization. Tirzepatide is in phase 3 development for adults with obesity, or overweight with weight-related comorbidity. It is also being studied as a potential treatment for people with obesity and/or overweight with heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and non-alcoholic steatohepatitis (NASH). Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are also ongoing.

Tirzepatide was approved by the FDA on May 13, 2022. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

INDICATION AND SAFETY SUMMARY WITH WARNINGS
Tirzepatide is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).

It is not known if Tirzepatide can be used in people who have had inflammation of the pancreas (pancreatitis). Tirzepatide is not for use in people with type 1 diabetes. It is not known if Tirzepatide is safe and effective for use in children under 18 years of age.
Warnings - Tirzepatide may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Tirzepatide if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
Do not use Tirzepatide if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use Tirzepatide if you are allergic to it or any of the ingredients in Tirzepatide.

Disclaimer